Actively Recruiting
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-04-15
20
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.
CONDITIONS
Official Title
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and postmenopausal women aged 50 years or older.
- Body Mass Index (BMI) 30 kg/m8.
- Untreated HbA1c less than 6.5% at baseline.
- Willingness and ability to comply with all study procedures, including fasting requirements.
- Able to provide informed consent and participate in all study assessments.
You will not qualify if you...
- Active diagnosis of type 2 diabetes mellitus, including use of glucose-lowering medications or HbA1c 6.5% or higher.
- Body Mass Index (BMI) 40 kg/m8 or higher.
- Moderate to severe gastroesophageal reflux disease.
- Inability to comply with the treatment protocol or understand the consent form.
- Chronic Kidney Disease Stage 4.
- Elevated liver enzymes: AST greater than 33 U/L or ALT greater than 36 U/L.
- Active pregnancy.
- Personal or family history of medullary thyroid carcinoma.
- Personal or family history of multiple endocrine neoplasia type 2 syndrome.
- Personal history of gastroparesis.
- Personal history of diabetic retinopathy.
- Known serious allergic reactions to Tirzepatide or its components.
- Known serious allergic reactions to any GLP-1 receptor agonist therapies.
- Current treatment with GLP-1 receptor agonist therapy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
S
Suha Soni
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here